EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation

Simone I Schulz, Marcus-Hillert Schultze-Mosgau, Anna Engelen, Nand Singh, Steve Pawsey, Klaus Francke, Ruth Lock, Antje Rottmann

European Journal of Drug Metabolism and Pharmacokinetics · 2025

DOI: 10.1007/s13318-024-00930-3 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2025. Verfasst von Simone I Schulz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Development-Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany. Hauptthemen laut MEDLINE: Neurokinin-1 Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NeRRe Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elinzanetant is a dual neurokinin-1,3 receptor antagonist in development for the treatment of menopausal vasomotor symptoms. The objectives of these studies were to characterize the mass balance and biotransformation of elinzanetant. METHODS: In the clinical evaluation, whole blood, plasma, urine, and feces were collected from healthy fasted male volunteers (n = 6) following a single dose of 120 mg [14C]-elinzanetant oral suspension for analysis of total radioactivity and metabolite profiling. In vitro reaction phenotyping and kinetics experiments on enzymes involved in elinzanetant metabolism were performed. RESULTS: On average, 90.8% of the total radioactivity administered was recovered in excreta over 480 h, mostly via the fecal route (feces 90.4%; urine 0.4%). Elinzanetant was rapidly absorbed and extensively metabolized but remained the main circulating species in plasma, accounting for 39.1% of total radioactivity. Known principal and active metabolites M27, M30/34, and M18/21 accounted for 7.6%, 13.7%, and 4.9% of total radioactivity in plasma, respectively. All other radiolabeled plasma components were each 10% of total radioactivity). In feces, metabolites resulting from oxidative biotransformation accounted, in sum, for ~ 40% of the dose, while elinzanetant remained the primary drug-related moiety. Results of in vitro experiments indicated that metabolism of elinzanetant was primarily mediated by cytochrome P450 3A4, with minor contribution from uridine 5'-diphospho-glucuronosyltransferase. CONCLUSIONS: Elinzanetant is metabolized mainly via oxidative biotransformation mediated by cytochrome P450 3A4, and primarily excreted in feces. The primary oxidation product M30/34 is a major human metabolite of elinzanetant. TRIAL REGISTRATION NUMBER: NCT04654897.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurokinin-1 Receptor AntagonistsAdultHumansMaleMiddle AgedYoung AdultAdministration, OralBiotransformationFecesHealthy Volunteers

Substanzen

Neurokinin-1 Receptor Antagonists

Autor:innen und Institutionen

  • Preclinical Development-Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany.
  • Early Clinical Development, Bayer AG, Berlin, Germany. marcus.schultze-mosgau@bayer.com.
  • Medical Department, Quotient Sciences, Nottingham, UK.
  • NeRRe Therapeutics Ltd, Stevenage, UK.
  • Early Clinical Development, Bayer AG, Berlin, Germany.
  • Aucuba Sciences Ltd, London, UK.

Förderung

  • NeRRe Therapeutics

Zitieren

APA

Schulz, S. I., Schultze-Mosgau, M. H., Engelen, A., Singh, N., Pawsey, S., Francke, K., Lock, R., & Rottmann, A. (2025). Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00930-3

Vancouver

Schulz SI, Schultze-Mosgau MH, Engelen A, Singh N, Pawsey S, Francke K, et al. Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation. European Journal of Drug Metabolism and Pharmacokinetics. 2025. doi:10.1007/s13318-024-00930-3

BibTeX
@article{Schulz2025,
  author = {Schulz, Simone I and Schultze-Mosgau, Marcus-Hillert and Engelen, Anna and Singh, Nand and Pawsey, Steve and Francke, Klaus and Lock, Ruth and Rottmann, Antje},
  title = {Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s13318-024-00930-3}
}
Kostenlos starten →